Generation Bio is a genetic medicines company creating a class of gene therapy utilizing its non-viral gene therapy platform. Co.'s non-viral gene therapy platform is comprised of three components: its high-capacity closed-ended DNA (ceDNA) construct, which can accommodate large or multiple genes as well as native regulatory elements; its cell-targeted lipid nanoparticle delivery system, which enables specific delivery of ceDNA to a range of tissues; and its established, scalable capsid-free manufacturing process, which uses a biologics infrastructure that has the potential to reach patients with rare diseases and to expand access to patients with prevalent diseases on a sustainable basis. The GBIO stock yearly return is shown above.
The yearly return on the GBIO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the GBIO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|